Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Kloess

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Sarcoma Research|May 17, 2012
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysisDagmar Berghuis, Marco W Schilham, Hanneke I Vos, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2008
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patientsDoreen Munkelt, Ulrike Koehl, Stephan Kloess, et al.
Frontiers in Immunology|September 26, 2017
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK SubsetStephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Oncoimmunology|October 21, 2016
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity <i>in vitro</i> and <i>in vivo</i> against chronic lymphocytic leukemiaMaulik Vyas, Ann-Charlott Schneider, Olga Shatnyeva, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2014
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapyClaudia Brehm, Sabine Huenecke, Ruth Esser, et al.
European Journal of Immunology|November 10, 2010
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICAStephan Kloess, Sabine Huenecke, Daniel Piechulek, et al.
Human Gene Therapy|February 9, 2019
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia ImmunotherapiesStephan Kloess, Olaf Oberschmidt, Julia Dahlke, et al.
Journal of Translational Medicine|July 23, 2015
Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantationBala Sai Sundarasetty, Stephan Kloess, Olaf Oberschmidt, et al.
Journal of Cellular and Molecular Medicine|May 21, 2011
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal originRuth Esser, Tina Müller, Dörthe Stefes, et al.
Plos One|November 19, 2011
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II studyClaudia Brehm, Sabine Huenecke, Andrea Quaiser, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Sarcoma Research|May 17, 2012
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysisDagmar Berghuis, Marco W Schilham, Hanneke I Vos, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2008
Cytotoxic effects of treosulfan and busulfan against leukemic cells of pediatric patientsDoreen Munkelt, Ulrike Koehl, Stephan Kloess, et al.
Frontiers in Immunology|September 26, 2017
Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK SubsetStephan Kloess, Alessa Ede Valverde da Silva, Olaf Oberschmidt, et al.
Oncoimmunology|October 21, 2016
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity <i>in vitro</i> and <i>in vivo</i> against chronic lymphocytic leukemiaMaulik Vyas, Ann-Charlott Schneider, Olga Shatnyeva, et al.
Cancer Immunology, Immunotherapy : CII|May 9, 2014
Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapyClaudia Brehm, Sabine Huenecke, Ruth Esser, et al.
European Journal of Immunology|November 10, 2010
IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICAStephan Kloess, Sabine Huenecke, Daniel Piechulek, et al.
Human Gene Therapy|February 9, 2019
Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia ImmunotherapiesStephan Kloess, Olaf Oberschmidt, Julia Dahlke, et al.
Journal of Translational Medicine|July 23, 2015
Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantationBala Sai Sundarasetty, Stephan Kloess, Olaf Oberschmidt, et al.
Journal of Cellular and Molecular Medicine|May 21, 2011
NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal originRuth Esser, Tina Müller, Dörthe Stefes, et al.
Plos One|November 19, 2011
IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant results to a phase I/II studyClaudia Brehm, Sabine Huenecke, Andrea Quaiser, et al.
Pageof 3